JPH1036350A - Purification of 4-hydroxypiperidine - Google Patents
Purification of 4-hydroxypiperidineInfo
- Publication number
- JPH1036350A JPH1036350A JP21193796A JP21193796A JPH1036350A JP H1036350 A JPH1036350 A JP H1036350A JP 21193796 A JP21193796 A JP 21193796A JP 21193796 A JP21193796 A JP 21193796A JP H1036350 A JPH1036350 A JP H1036350A
- Authority
- JP
- Japan
- Prior art keywords
- hydroxypiperidine
- purity
- crystals
- crude
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Hydrogenated Pyridines (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は4−ヒドロキシピペ
リジンの精製方法に関する。4−ヒドロキシピペリジン
は医薬及び農薬の原料として有用な化合物であり、例え
ば、向精神薬として知られているプロペリシアジンなど
の原料として利用されている。TECHNICAL FIELD The present invention relates to a method for purifying 4-hydroxypiperidine. 4-Hydroxypiperidine is a compound useful as a raw material for medicines and agricultural chemicals, and is used as a raw material for propericiazine, for example, which is known as a psychotropic drug.
【0002】[0002]
【従来の技術】従来、4−ヒドロキシピペリジンの精製
方法としては、粗製4−ヒドロキシピペリジンを蒸留
により精製する方法、粗製4−ヒドロキシピペリジン
を塩酸の付加塩とした後に4−ヒドロキシピペリジンを
単離して精製する方法が知られている。2. Description of the Related Art Conventionally, as a method for purifying 4-hydroxypiperidine, a method of purifying crude 4-hydroxypiperidine by distillation, a method of converting crude 4-hydroxypiperidine into an addition salt of hydrochloric acid, and then isolating 4-hydroxypiperidine. Methods for purification are known.
【0003】の方法は、4−ヒドロキシピペリジンが
昇華性を有し、融点が89〜92℃の固体であるため、
蒸留操作が困難である。また、該化合物は吸湿性を有す
るため、蒸留後粉砕して粉体とする際にも湿気を遮断し
なければならず操作が煩雑であり、蒸留精製する方法で
は特殊な装置が必要であるという問題点がある。According to the method, 4-hydroxypiperidine has a sublimability and is a solid having a melting point of 89 to 92 ° C.
Distillation operation is difficult. In addition, since the compound has hygroscopicity, it is necessary to shut off moisture even when pulverized after distillation to obtain a powder, the operation is complicated, and a special apparatus is required in the method of purification by distillation. There is a problem.
【0004】の方法は、粗製4−ヒドロキシピペリジ
ンをメタノール、エタノール、イソプロパノールなどの
アルコール溶媒中で安定的な酸の付加塩として再結晶さ
せ、ろ取、乾燥して4−ヒドロキシピペリジン塩酸塩を
得るが、該化合物から4−ヒドロキシピペリジンを単離
するには、アルカリ水溶液で中和した後に有機溶媒で抽
出し、有機層を水洗して乾燥後に溶媒を留去又は蒸留す
るといった煩雑な操作となる。の方法も最終的に粉砕
処理をすることになるのでの方法と同様な問題点を含
んでいる。According to the method of (1), crude 4-hydroxypiperidine is recrystallized as a stable acid addition salt in an alcoholic solvent such as methanol, ethanol or isopropanol, and then filtered and dried to obtain 4-hydroxypiperidine hydrochloride. However, in order to isolate 4-hydroxypiperidine from the compound, a complicated operation such as neutralization with an aqueous alkali solution, extraction with an organic solvent, washing of the organic layer with water and drying, followed by distilling off or distilling off the solvent, is required. . The method (1) also has the same problem as the method in which the pulverization is finally performed.
【0005】以上のように、4−ヒドロキシピペリジン
を精製する技術は工業的に確立されていなかった。[0005] As described above, the technology for purifying 4-hydroxypiperidine has not been industrially established.
【0006】[0006]
【発明が解決しようとする課題】本発明の目的は、4−
ヒドロキシピペリジンを工業的に容易な方法で高純度に
精製する方法を提供する点にある。SUMMARY OF THE INVENTION An object of the present invention is to provide 4-
An object of the present invention is to provide a method for purifying hydroxypiperidine with high purity by an industrially easy method.
【0007】[0007]
【課題を解決するための手段】本発明者らは前記問題点
を解決すべく鋭意検討を重ねた結果、粗製4−ヒドロキ
シピペリジンを有機溶媒を用いて再結晶させることによ
り高純度の結晶体としての該化合物を得る方法を見いだ
し、本発明を完成するにいたった。The present inventors have made intensive studies to solve the above problems, and as a result, recrystallized crude 4-hydroxypiperidine using an organic solvent to obtain high-purity crystals. The present inventors have found a method for obtaining the above compound, and have completed the present invention.
【0008】再結晶に用いる有機溶媒は、4−ヒドロキ
シピペリジンを適宜溶解する有機溶媒であれば特に制限
はなく、例えば、アセトン、メチルエチルケトンなどの
ケトン類、テトラヒドロフラン(THF)、ジメトキシ
メタン、1,2−ジメトキシエタンなどのエーテル類、
酢酸メチル、酢酸エチルなどのエステル類(第1溶媒)
などが挙げられる。これらは単独で使用するか又は2種
以上を組み合わせて使用してもよい。貧溶媒であるヘキ
サン、シクロヘキサン、メチルシクロヘキサン、トルエ
ンなどの炭化水素類を使用する際は、第1溶媒と組み合
わせて使用すればよい。また、良溶媒であるメタノー
ル、エタノール、イソプロパノールなどのアルコール類
は単独では使用に適さないが、貧溶媒との組み合わせで
使用することができる。単独で使用する際の好ましい溶
媒は、4−ヒドロキシピペリジンの結晶を乾燥しやすい
低沸点のアセトンである。The organic solvent used for the recrystallization is not particularly limited as long as it is an organic solvent capable of appropriately dissolving 4-hydroxypiperidine, and examples thereof include ketones such as acetone and methyl ethyl ketone, tetrahydrofuran (THF), dimethoxymethane, Ethers such as dimethoxyethane,
Esters such as methyl acetate and ethyl acetate (first solvent)
And the like. These may be used alone or in combination of two or more. When using hydrocarbons such as hexane, cyclohexane, methylcyclohexane, and toluene, which are poor solvents, they may be used in combination with the first solvent. Alcohols such as methanol, ethanol and isopropanol, which are good solvents, are not suitable for use alone, but can be used in combination with poor solvents. A preferred solvent when used alone is low boiling acetone which tends to dry the crystals of 4-hydroxypiperidine.
【0009】有機溶媒は単独で使用する場合、4−ヒド
ロキシピペリジンに対して通常2〜15重量倍量使用す
るが、溶媒の該化合物に対する溶解度によって用いる溶
媒の量を適宜加減すればよい。再結晶は、使用する有機
溶媒の沸点付近の温度で溶解させた後に徐冷して晶析さ
せる。When the organic solvent is used alone, it is usually used in an amount of 2 to 15 times the weight of 4-hydroxypiperidine, but the amount of the solvent may be appropriately adjusted depending on the solubility of the solvent in the compound. The recrystallization is performed by dissolving at a temperature around the boiling point of the organic solvent to be used and then slowly cooling to crystallize.
【0010】再結晶の際に活性炭や活性白土などを加え
て熱時に4−ヒドロキシピペリジンが溶解している状態
で脱色処理することも精製には効果的である。[0010] It is also effective for purification to add activated carbon or activated clay at the time of recrystallization and to perform a decolorization treatment in a state where 4-hydroxypiperidine is dissolved when heated.
【0011】なお、再結晶で得られた4−ヒドロキシピ
ペリジンは、常法に従って、ろ取、乾燥することにより
最終製品とすることができる。The 4-hydroxypiperidine obtained by recrystallization can be filtered and dried according to a conventional method to obtain a final product.
【0012】[0012]
【実施例】以下、実施例にて本発明を更に説明するが、
本発明はこれにより何ら限定されるものではない。EXAMPLES Hereinafter, the present invention will be further described with reference to Examples.
The present invention is not limited thereby.
【0013】実施例1 攪拌機、温度計、冷却器を備えた5L四つ口フラスコ
に、ガククロマトグラフィー(GC)純度93.6%の
粗製4−ヒドロキシピペリジン930.3g、アセトン
1860.6gを仕込み、60℃に加熱溶解して熱時に
活性炭9.3gで処理した後、氷水で冷却して再結晶を
行い、結晶をろ取し、乾燥(70℃/15Torr、4
時間)したところ、白色柱状結晶の4−ヒドロキシピペ
リジン874.1gを得た。GC純度は99.9%であ
った。0.01%は残留溶媒であった。Example 1 In a 5 L four-necked flask equipped with a stirrer, a thermometer, and a condenser, 930.3 g of crude 4-hydroxypiperidine having a purity of 93.6% by gac chromatography (GC) and 1860.6 g of acetone were charged. After heating and dissolving at 60 ° C. and treating it with 9.3 g of activated carbon while hot, recrystallization was performed by cooling with ice water, and the crystals were collected by filtration and dried (70 ° C./15 Torr, 4 ° C.).
After that, 874.1 g of 4-hydroxypiperidine as white columnar crystals was obtained. GC purity was 99.9%. 0.01% was residual solvent.
【0014】実施例2 攪拌機、温度計、冷却器を備えた500mL四つ口フラ
スコに、GC純度98.6%の粗製4−ヒドロキシピペ
リジン69.5g、THF208.5gを仕込み、66
℃に加熱溶解した後、氷水で冷却して再結晶を行い、結
晶をろ取し、乾燥(60℃/5Torr、3時間)した
ところ、白色針状結晶の4−ヒドロキシピペリジン6
5.9gを得た。GC純度は99.8%であった。0.
2%は残留溶媒であった。Example 2 A 500 mL four-necked flask equipped with a stirrer, a thermometer and a condenser was charged with 69.5 g of crude 4-hydroxypiperidine having a GC purity of 98.6% and 208.5 g of THF.
After heating and dissolving the mixture at 0 ° C., the mixture was cooled with ice water to perform recrystallization. The crystals were collected by filtration and dried (60 ° C./5 Torr, 3 hours) to give 4-hydroxypiperidine 6 as white needle crystals.
5.9 g were obtained. GC purity was 99.8%. 0.
2% was residual solvent.
【0015】実施例3 攪拌機、温度計、冷却器を備えた2L四つ口フラスコ
に、GC純度98.6%の粗製4−ヒドロキシピペリジ
ン69.4g、ジメトキシメタン1041.0gを仕込
み、43℃に加熱溶解した後、氷水で冷却して再結晶を
行い、結晶をろ取し、乾燥(60〜70℃/25〜35
Torr、5時間)したところ、白色針状結晶の4−ヒ
ドロキシピペリジン51.9gを得た。GC純度は9
9.9%であった。0.1%は残留溶媒であった。Example 3 69.4 g of crude 4-hydroxypiperidine having a GC purity of 98.6% and 1041.0 g of dimethoxymethane were charged into a 2 L four-necked flask equipped with a stirrer, a thermometer, and a cooler. After heating and dissolving, the mixture is cooled with ice water to perform recrystallization, and the crystals are collected by filtration and dried (60 to 70 ° C / 25 to 35
(Torr, 5 hours) to obtain 51.9 g of 4-hydroxypiperidine as white needle crystals. GC purity is 9
9.9%. 0.1% was residual solvent.
【0016】実施例4 攪拌機、温度計、冷却器を備えた500mL四つ口フラ
スコに、GC純度96.9%の粗製4−ヒドロキシピペ
リジン62.1g、1,2−ジメトキシエタン240.
0gを仕込み、87℃に加熱溶解し、熱時に活性炭0.
62で処理した後、氷水で冷却して再結晶を行い、結晶
をろ取し、乾燥(60℃/2Torr、4時間)したと
ころ、白色針状結晶の4−ヒドロキシピペリジン51.
0gを得た。GC純度は99.7%であった。0.3%
は残留溶媒であった。Example 4 In a 500 mL four-necked flask equipped with a stirrer, a thermometer and a condenser, 62.1 g of crude 4-hydroxypiperidine having a GC purity of 96.9%, 1,2-dimethoxyethane 240.
0 g was charged and dissolved at 87 ° C. by heating.
After the treatment in Step 62, recrystallization was performed by cooling with ice water, and the crystals were collected by filtration and dried (60 ° C./2 Torr, 4 hours) to give 4-hydroxypiperidine as white needle crystals.
0 g was obtained. GC purity was 99.7%. 0.3%
Was the residual solvent.
【0017】実施例5 攪拌機、温度計、冷却器を備えた1L四つ口フラスコ
に、GC純度98.1%の粗製4−ヒドロキシピペリジ
ン128.5g、酢酸エチル400.0gを仕込み、7
3℃に加熱溶解した後、氷水で冷却して再結晶を行い、
結晶をろ取し、乾燥(40℃/2Torr、4時間)し
たところ、白色微細針状結晶の4−ヒドロキシピペリジ
ン120.6gを得た。GC純度は99.2%であっ
た。0.8%は残留溶媒であった。Example 5 A 1L four-necked flask equipped with a stirrer, a thermometer and a condenser was charged with 128.5 g of crude 4-hydroxypiperidine having a GC purity of 98.1% and 400.0 g of ethyl acetate.
After heating and melting at 3 ° C, it was cooled with iced water and recrystallized.
The crystals were collected by filtration and dried (40 ° C./2 Torr, 4 hours) to obtain 120.6 g of 4-hydroxypiperidine as white fine needle crystals. GC purity was 99.2%. 0.8% was residual solvent.
【0018】実施例6 攪拌機、温度計、冷却器を備えた100mL四つ口フラ
スコに、GC純度98.5%の4−ヒドロキシピペリジ
ン10.0g、トルエン27.0g、イソプロパノール
4.8gを仕込み、101℃に加熱溶解した後、氷水で
冷却して再結晶を行い、結晶をろ取し、乾燥(40〜7
0℃/2Torr、3時間)したところ、白色微細針状
結晶の4−ヒドロキシピペリジン8.0gを得た。GC
純度は99.8%であった。0.2%は残留溶媒であっ
た。Example 6 10.0 g of 4-hydroxypiperidine having a GC purity of 98.5%, 27.0 g of toluene, and 4.8 g of isopropanol were charged into a 100 mL four-necked flask equipped with a stirrer, a thermometer, and a cooler. After heating and melting at 101 ° C., the mixture was cooled with ice water to perform recrystallization, and the crystals were collected by filtration and dried (40 to 7).
At 0 ° C./2 Torr for 3 hours), 8.0 g of 4-hydroxypiperidine as fine white needle-like crystals was obtained. GC
Purity was 99.8%. 0.2% was residual solvent.
【0019】[0019]
【発明の効果】本発明によれば、医薬及び農薬の原料と
して有用な4−ヒドロキシピペリジンを工業的に容易な
方法で高純度に精製することができる。According to the present invention, 4-hydroxypiperidine, which is useful as a raw material for medicines and agricultural chemicals, can be purified to a high purity by an industrially easy method.
Claims (1)
媒を用いて再結晶させることにより高純度の柱状または
針状結晶体を得ることを特徴とする4−ヒドロキシピペ
リジンの精製方法。1. A method for purifying 4-hydroxypiperidine, comprising recrystallizing crude 4-hydroxypiperidine using an organic solvent to obtain a high-purity columnar or needle-like crystal.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP21193796A JP2920617B2 (en) | 1996-07-23 | 1996-07-23 | Purification method of 4-hydroxypiperidine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP21193796A JP2920617B2 (en) | 1996-07-23 | 1996-07-23 | Purification method of 4-hydroxypiperidine |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH1036350A true JPH1036350A (en) | 1998-02-10 |
JP2920617B2 JP2920617B2 (en) | 1999-07-19 |
Family
ID=16614160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP21193796A Expired - Lifetime JP2920617B2 (en) | 1996-07-23 | 1996-07-23 | Purification method of 4-hydroxypiperidine |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2920617B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008546851A (en) * | 2006-08-14 | 2008-12-25 | テバ ファーマシューティカル インダストリーズ リミティド | Pure paliperidone and its production |
JP2013213004A (en) * | 2012-04-02 | 2013-10-17 | Dainippon Printing Co Ltd | Method for producing olanzapine |
-
1996
- 1996-07-23 JP JP21193796A patent/JP2920617B2/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008546851A (en) * | 2006-08-14 | 2008-12-25 | テバ ファーマシューティカル インダストリーズ リミティド | Pure paliperidone and its production |
JP2013213004A (en) * | 2012-04-02 | 2013-10-17 | Dainippon Printing Co Ltd | Method for producing olanzapine |
Also Published As
Publication number | Publication date |
---|---|
JP2920617B2 (en) | 1999-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2577331C2 (en) | Crystalline base of minocycline and methods for obtaining thereof | |
JP4298212B2 (en) | Method for producing high melting point type epinastine hydrochloride | |
WO2002034713A1 (en) | Process for producing b-form nateglinide crystal | |
JPS5935381B2 (en) | Method for resolving (+)- and (-)-6-methoxy-α-methyl-2-naphthaleneacetic acid | |
IL101358A (en) | Crystalline tiagabine hydrochloride monohydrate its preparation and pharmaceutical composition containing it | |
SU1138029A3 (en) | Method of obtaining 5-substituted 1,2-dihydro-3h-pyrrolo-(1,2-a)-pyrrol-1-carbonic acids | |
US8252922B2 (en) | Method for crystallizing sucralose | |
JP3347189B2 (en) | Quinic acid derivative and method for producing the same | |
JP2920617B2 (en) | Purification method of 4-hydroxypiperidine | |
Toki | Studies on sarkomycin–optically active 2-methylenecyclopentanone-3-carboxylic acids | |
US2500444A (en) | Uramidohomomeroquinene | |
KR860001228B1 (en) | Process for the optical resolution of mixtures of d-and-l- -(6-methoxy- -naphtyhl)-propionic acids | |
JP6670744B2 (en) | Polymorphic forms of sodium hyodeoxycholate (NaHDC) and methods for their preparation | |
JPH10279577A (en) | Lactide for food additive and purification of lactide | |
EP1564209A1 (en) | Process for the preparation of 13-cis-retinoic acid | |
JP4105797B2 (en) | Method for purifying optically active α-trifluoromethyl lactic acid | |
HU201011B (en) | Process for producing optically active oxoisoindolinyl derivatives and pharmaceutical compositions comprising such compounds | |
US20030135065A1 (en) | Process for the production of L-DOPA ethyl ester | |
WO2007110884A2 (en) | A process for the preparation of highly pure anhydrous fexofenadine hydrochloride | |
JPH08217764A (en) | Selective recovery of crystals of benzylidene derivative | |
WO2005054211A1 (en) | A method of purification of lorazepam | |
JP2007217440A (en) | Purification method for optically active alpha-trifluoromethyl lactate | |
SU328572A1 (en) | METHOD FOR OBTAINING N-ACYL-a-AMINO ACID AMIDES OR PEPTIDES | |
JPH0798802B2 (en) | Process for producing optically active indoline-2-carboxylic acid | |
JP2761973B2 (en) | Process for producing easily crushable cis-2-methylspiro (1,3-oxathiolane-5,3 ') quinuclidine hydrochloride hemihydrate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090430 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100430 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110430 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120430 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130430 Year of fee payment: 14 |
|
EXPY | Cancellation because of completion of term |